Cue Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary

Cue Biopharma

14/08/2026 22:37

Cue Biopharma, Inc. CUE.OQ reported a quarterly adjusted loss of $13.81​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $-2.70.  The lone analyst forecast for the quarter was for a loss of $1.69 per share. 
Revenue rose 166.7% to $7.88 million from a year ago; analysts expected $3.00 million. 
Cue Biopharma, Inc.'s reported EPS for the quarter was a loss of $24.14​.
The company reported a quarterly loss of $153.07 million.
Cue Biopharma, Inc. shares had fallen by 1.5% this quarter and gained 239.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Cue Biopharma, Inc. is $115.00, about 73% above its last closing price of $31.08
This summary was machine generated from LSEG data August 14 at 09:37 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-1.69
-13.81
Missed
 
-1.08
 
0.30
Sep. 30 2025 
-2.80
-2.10
Beat